FSD Pharma Stock Surges 200% as unbuzzd™ Set to Shake Up the Recovery Market
PRISM Emerging Psychedelic Index top gainer, FSD Pharma Inc. (NASDAQ: HUGE) saw its shares skyrocket by 200% today after providing an update on its investment in Celly Nutrition Corp., a Canadian company set to launch an innovative product, unbuzzd™, later this month. Celly Nutrition, supported by FSD Pharma’s pharmaceutical research and development team, is introducing unbuzzd™ stick packs, a beverage designed to expedite alcohol metabolism and facilitate faster recovery from alcohol consumption.
The launch of unbuzzd™, which will be available on Amazon in convenient three-pack and eighteen-pack formats, aims to capture its share of the recovery solutions market. Unlike traditional recovery drinks that focus on alleviating hangover symptoms, unbuzzd™ is designed to help the body process alcohol more quickly, restore mental clarity, and improve cognition, offering a new approach to responsible alcohol consumption.
The product’s development is backed by industry veterans, including John Duffy, CEO of Celly Nutrition and former Coca-Cola executive, and Gerry David, the former CEO of Celsius Holdings. This expert leadership, combined with the product’s innovative, science-driven formulation, positions unbuzzd™ as a potential game-changer in the wellness and recovery supplement market.
To support the rollout, Celly Nutrition has successfully closed the first tranche of financing, raising over $200,000. The company plans to use the proceeds to advance its business plans and further develop its product lineup, with 12oz Ready to Drink (RTD) cans expected to join the unbuzzd™ family later this year.
FSD Pharma’s big investment in Celly Nutrition and the buzz around unbuzzd™ have investors buzzed, causing a 200% jump in FSD Pharma’s stock.
In addition to its recovery beverage product launch, FSD Pharma is focused on developing innovative biotech solutions for neurodegenerative, metabolic, and alcohol misuse disorders. Through its subsidiary, Lucid Psycheceuticals, FSD is advancing its lead compound, Lucid-MS, which has shown promise in preclinical models for treating multiple sclerosis by preventing and reversing myelin degradation.
